Two Sigma Investments’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.88M Buy
+13,500
New +$1.89M ﹤0.01% 2796
2025
Q2
Sell
-43,400
Closed -$4.86M 3304
2025
Q1
$4.86M Sell
43,400
-196,562
-82% -$20.3M 0.01% 1151
2024
Q4
$22.2M Sell
239,962
-458,712
-66% -$41.3M 0.05% 445
2024
Q3
$58.6M Sell
698,674
-2,634,933
-79% -$201M 0.13% 194
2024
Q2
$229M Buy
3,333,607
+136,934
+4% +$9.14M 0.52% 24
2024
Q1
$234M Buy
3,196,673
+3,177,673
+16,725% +$244M 0.55% 15
2023
Q4
$1.54M Sell
19,000
-2,438,656
-99% -$190M ﹤0.01% 1793
2023
Q3
$184M Buy
2,457,656
+1,602,283
+187% +$123M 0.5% 34
2023
Q2
$65.9M Sell
855,373
-1,513,653
-64% -$121M 0.17% 163
2023
Q1
$197M Sell
2,369,026
-586,766
-20% -$48.6M 0.56% 22
2022
Q4
$254M Sell
2,955,792
-605,147
-17% -$47.9M 0.8% 3
2022
Q3
$220M Buy
3,560,939
+355,044
+11% +$22.4M 0.75% 14
2022
Q2
$198M Buy
3,205,895
+664,765
+26% +$41.2M 0.65% 26
2022
Q1
$151M Buy
2,541,130
+1,085,059
+75% +$69.4M 0.45% 38
2021
Q4
$106M Sell
1,456,071
-1,669,899
-53% -$115M 0.23% 107
2021
Q3
$218M Buy
3,125,970
+2,392,373
+326% +$168M 0.49% 24
2021
Q2
$50.5M Buy
+733,597
New +$49M 0.11% 203
2021
Q1
Sell
-155,878
Closed -$10.1M 3970
2020
Q4
$9.08M Buy
+155,878
New +$9.41M 0.03% 636
2020
Q2
Sell
-35,773
Closed -$2.74M 3158
2020
Q1
$2.67M Sell
35,773
-197,232
-85% -$13.6M 0.02% 815
2019
Q4
$15.1M Sell
233,005
-680,479
-74% -$44.3M 0.05% 460
2019
Q3
$57.9M Sell
913,484
-1,560,212
-63% -$102M 0.19% 130
2019
Q2
$167M Sell
2,473,696
-350,685
-12% -$23.1M 0.56% 14
2019
Q1
$184M Buy
2,824,381
+947,758
+51% +$63M 0.6% 9
2018
Q4
$117M Buy
1,876,623
+1,250,898
+200% +$87.4M 0.46% 32
2018
Q3
$48.3M Buy
625,725
+343,520
+122% +$25.9M 0.13% 218
2018
Q2
$20M Buy
282,205
+228,720
+428% +$16.2M 0.06% 411
2018
Q1
$4.03M Sell
53,485
-355,720
-87% -$28.3M 0.01% 1077
2017
Q4
$29.3M Sell
409,205
-313,068
-43% -$23.8M 0.1% 280
2017
Q3
$58.5M Sell
722,273
-1,687,716
-70% -$129M 0.21% 133
2017
Q2
$171M Buy
2,409,989
+916,595
+61% +$61M 0.62% 9
2017
Q1
$101M Sell
1,493,394
-891,518
-37% -$62.7M 0.34% 49
2016
Q4
$171M Buy
2,384,912
+399,107
+20% +$29.7M 0.65% 5
2016
Q3
$157M Buy
1,985,805
+1,894,500
+2,075% +$154M 0.57% 21
2016
Q2
$7.62M Sell
91,305
-1,119,848
-92% -$99.4M 0.03% 584
2016
Q1
$111M Buy
1,211,153
+997,922
+468% +$90M 0.53% 26
2015
Q4
$21.6M Sell
213,231
-1,519,260
-88% -$158M 0.1% 233
2015
Q3
$170M Buy
1,732,491
+364,251
+27% +$40.5M 0.87% 3
2015
Q2
$160M Buy
1,368,240
+507,925
+59% +$55.5M 0.75% 6
2015
Q1
$84.4M Buy
860,315
+731,911
+570% +$74.3M 0.39% 42
2014
Q4
$12.1M Sell
128,404
-951,461
-88% -$98.4M 0.07% 361
2014
Q3
$115M Buy
+1,079,865
New +$106M 0.51% 27
2014
Q2
Sell
-4,748
Closed -$336K 2216
2014
Q1
$336K Sell
4,748
-50,151
-91% -$3.93M ﹤0.01% 1631
2013
Q4
$4.13M Sell
54,899
-162,290
-75% -$11.3M 0.02% 697
2013
Q3
$13.6M Buy
217,189
+212,441
+4,474% +$12.7M 0.09% 273
2013
Q2
$243K Buy
+4,748
New +$247K ﹤0.01% 1708

Other funds holding GILD

Two Sigma Investments's GILD Position: Q1 2026 in Review

Two Sigma Investments opened a new position in Gilead Sciences (GILD) in Q1 2026: 13,500 shares worth $1.88M. The stake represents ﹤0.01% of the portfolio and ranks #2796 among its holdings. This is a return to the name: Two Sigma Investments previously reported a position in GILD as recently as Q1 2025.

Two Sigma Investments first reported a position in GILD in Q2 2013 and has held it in 45 quarters since. The position peaked at $254M in Q4 2022. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Two Sigma Investments held 13,500 shares of Gilead Sciences worth $1.88M as of Q1 2026.
  • Gilead Sciences was a new Two Sigma Investments position in Q1 2026.
  • Gilead Sciences made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #2796 holding.
  • Two Sigma Investments first reported a position in Gilead Sciences in Q2 2013 and has held it in 45 quarters since.
  • Two Sigma Investments's Gilead Sciences position peaked at $254M in Q4 2022.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.